On July 6, Alibaba Health rose 3.04% in regular trading, trading at HK$3.4/share, with turnover of HK$63.25 million, extending its recent upward momentum.

On the news front, the company's innovative drug launch platform effect continues to gain traction. On June 29, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first self-developed highly selective URAT1 inhibitor for gout) and Yangtze River Pharmaceuticals' Class 1 new drug Taitoto (a next-generation PDE5 inhibitor for erectile dysfunction) both launched exclusively on Alibaba Health. On July 1, Jiudian Pharmaceutical's Jiuyue Loxoprofen Sodium Gel Patch also chose Alibaba Health for its nationwide online debut. The intensive onboarding of multiple innovative drugs reinforces the company's positioning as a premier online launch channel for new and specialty pharmaceuticals, validating its commercial value and digital service capabilities in the innovative drug commercialization chain. Management has previously guided FY2027 revenue growth of 10% to 15%, with innovative drug categories identified as the core growth driver.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)